Phase IIb Data Show Investigational Once-Weekly DPP-4 Inhibitor MK-3102 Significantly Lowers Blood Sugar In Patients With Type 2 Diabetes

New data announced at the 48th European Association for the Study of Diabetes (EASD) annual meeting show Merck Sharp & Dohme's (MSD) investigational once-weekly DPP-4 inhibitor significantly lowers blood sugar compared with placebo in patients with type 2 diabetes. The 12 week study also shows that treatment with MK-3102 is associated with an incidence of symptomatic hypoglycaemia similar to placebo, in patients with type 2 diabetes...
Read more »

Excellent Interim Results Reported From Phase I/II Study With Anti-IL-6R Nanobody, ALX-0061, In Rheumatoid Arthritis Patients

Ablynx [Euronext Brussels: ABLX] has announced that its anti-IL-6R Nanobody, ALX-0061, met the efficacy endpoint of a significant improvement in key indicators of disease activity at the 12 week interim analysis of the Phase I/II study in patients with moderate to severe active rheumatoid arthritis (RA) on a stable background of methotrexate. Final 24 week results are expected in the first quarter of 2013. In this Phase I/II study, 37 RA patients were recruited to the multiple dose Phase II part...
Read more »

Circassia Initiates Pivotal Phase 3 ToleroMune® Trial In Cat Allergen-Induced Rhinoconjunctivitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, has announced the start of a pivotal phase 3 trial of its investigational ToleroMune(R) cat allergy treatment for cat allergen-induced rhinoconjunctivitis...
Read more »